Betahistine for Meniere's Disease: Does it Work?
Betahistine for Meniere's disease does not appear to work: the strongest placebo-controlled trial found no reduction in vertigo attacks, and systematic reviews rate the evidence as insufficient or very low certainty. Betahistine targets endolymphatic hydrops, but hydrops appears to be a downstream consequence of Meniere's disease rather than its cause. Newer treatment models instead use multimodal rehabilitation to address both the disease and its broader neurological effects.
WHAT OUR PATIENTS WANT TO KNOW
| Topic | Quick Answer |
| Does betahistine work? | The best evidence says no. The strongest placebo-controlled trial found no reduction in Meniere's vertigo attacks, and systematic reviews rate the evidence as insufficient or very low certainty. |
| How is it supposed to work? | Betahistine is thought to increase inner-ear blood flow and reduce endolymphatic hydrops, a mechanism increasingly questioned as the primary cause of Meniere's disease. |
| Dosage and side effects | Typical dosing is 24–48 mg daily in divided doses (usually 3 times a day). Common side effects include headache, nausea, and indigestion, which are usually mild. |
| US availability | Betahistine is not FDA-approved in the US and generally requires a compounding pharmacy or Canadian pharmacy, although it remains widely prescribed internationally. |
Betahistine remains one of the most widely prescribed treatments for Meniere's disease worldwide, yet the best clinical trial found that it performed no better than placebo.
The bigger question is why a treatment with such weak evidence remains so widely used. Below, we look at both the evidence for betahistine and the disease model behind it.
IMPORTANT: If you're still struggling with Meniere's disease despite betahistine or other conventional treatments, schedule a Program Consultation with our team to discuss the new treatment approach for Meniere's.
SPECIALIST PERSPECTIVE
Betahistine for Meniere's disease is a treatment built more on tradition than evidence. The clinical evidence is weak, but the deeper problem is that the theory behind the treatment may also be wrong. Betahistine targets endolymphatic hydrops, yet hydrops increasingly appears to be a downstream consequence of Meniere's disease rather than its cause. If migraine-related neural and vascular dysfunction is the upstream driver, betahistine may be targeting the wrong mechanism entirely.
Does Betahistine Work for Meniere's Disease?
Betahistine does not appear to work for Meniere's disease, according to the best available evidence. The strongest placebo-controlled trial found no reduction in vertigo attacks compared with placebo, while recent systematic reviews conclude that the evidence supporting betahistine is insufficient or very low certainty [1-3].
Some studies do report improvement with betahistine. However, these are generally lower-quality or uncontrolled studies that cannot establish whether betahistine itself caused the improvement.
The BEMED Trial: The Best Evidence on Betahistine for Meniere's
The BEMED trial is the strongest clinical trial of betahistine for Meniere's disease because it directly compared the drug against placebo [3].
The study included:
- 221 patients with confirmed Meniere's disease
- Placebo, low-dose betahistine, and high-dose betahistine groups
- 9 months of treatment
- Vertigo attacks per month as the primary outcome
KEY RESULT: Betahistine performed no better than placebo.
Vertigo attacks decreased in all three groups, but neither low-dose nor high-dose betahistine reduced attacks more than placebo. Increasing the dose did not improve the result [3].
The 2021 systematic review and 2023 Cochrane review reached similarly cautious conclusions, finding insufficient or very low-certainty evidence that betahistine benefits patients with Meniere's disease [1-2].
Does Betahistine Help Hearing Loss in Meniere's Disease?
There is no reliable evidence that betahistine prevents or improves hearing loss in Meniere's disease. Although it was originally expected to protect hearing by improving inner-ear blood flow, clinical trials have not demonstrated this benefit. In the BEMED trial, hearing outcomes did not improve and actually trended slightly worse with betahistine compared with placebo [1,3].
Why Do Some Studies Show a Benefit From Betahistine?
Some lower-quality studies have reported benefit. A 2016 Cochrane review found about a 30% greater rate of improvement in vertigo symptoms, but it pooled small, lower-quality studies involving multiple causes of vertigo, not just Meniere's disease [4].
More recently, a 2021 retrospective study of 105 Meniere's patients reported significant improvement in vertigo frequency and duration [5]. However, without a placebo or untreated control group, it cannot determine whether the improvement came from betahistine or the natural fluctuation of Meniere's disease.
This is especially important for Meniere’s disease attacks which tend to come in clusters, where people get a number of attacks in a row then may have an interval where they do not get any attacks or only mild symptoms.
“I used to plan my whole life around the dizziness. Now I finally feel like myself again.”
—Sarah C.
Are you a good candidate for our approach?
What Do Meniere's Disease Guidelines Say About Betahistine?
The 2020 AAO-HNS guideline says clinicians “may offer” betahistine, but grades it only as an “Option,” its weakest recommendation level [6]. The committee cited BEMED as “the best evidence we have” and concluded it was “unable to make a definitive statement” about betahistine for controlling Meniere's symptoms.
Internationally, betahistine remains widely used, but no major guideline strongly endorses it based on high-quality evidence. The 2023 Cochrane review similarly rates the evidence for vertigo control as very low certainty [1].
How Widely is Betahistine for Meniere’s Being Prescribed?
Yes, and very widely, albeit not in the United States. Despite the weak trial evidence, betahistine remains standard maintenance therapy for Meniere's disease across much of Europe and Asia [1].
- About 85% of UK ENT surgeons report prescribing betahistine
- About 78% of Italian ENT surgeons use it as maintenance therapy
- It remains the first-line pharmacological treatment for Meniere's disease in many European and Asian countries [1]
This creates a real disconnect: the countries that prescribe betahistine most often are not doing so because of stronger evidence than what's available in the US. They're continuing a decades-old practice that predates the trials now calling its effectiveness into question.
Betahistine for Meniere’s: Dosage and Side Effects
Betahistine is generally well tolerated, and typical dosing varies based on the source:
- Clinical trial doses: The BEMED trial tested a low dose (48 mg/day) and a high dose (144 mg/day), finding no difference in effectiveness between them [3]
- Real-world dosing: Observational data suggests average doses closer to 87.5 mg/day, individualized per patient rather than fixed [5].
Common side effects are mild and include headache, nausea, and stomach upset. Betahistine should be used with caution in people with asthma or a history of peptic ulcer disease, and should be avoided in people with pheochromocytoma, a rare adrenal tumor [7].
Why Isn't Betahistine for Meniere's Disease FDA-Approved?
Betahistine is not FDA-approved for Meniere's disease in the United States because its effectiveness has not been established to the standard required for approval. This is primarily an efficacy issue, not a safety issue: betahistine has a long international safety record, with more than 130 million patients exposed worldwide [7].
In the US, betahistine is available only through compounding pharmacies. Betahistine was approved by the FDA about 50 years ago for approximately five years under the brandname “Serc”. The FDA approval was withdrawn because lack of evidence for efficacy in 1972.
Betahistine was reviewed again by FDA in June of 1999. This time, the issue was not to approve it for wide use, but to place it on a special bulk substances list that allows compounding pharmacies to legally custom-make it for patients.
Is Betahistine Still Being Studied?
Yes. Because oral betahistine has low bioavailability (a lot of it doesn’t get absorbed), researchers are investigating whether better drug delivery could improve its effectiveness. Recent studies have explored intranasal betahistine, increasing absorption with selegiline, and direct intratympanic delivery [8-10]. However, none of these newer approaches has yet been shown to improve outcomes in patients with Meniere's disease.
How Does Betahistine Work for Meniere's Disease?
Betahistine is thought to work for Meniere's disease by increasing blood flow within the inner ear and improving the regulation of endolymph, the fluid involved in endolymphatic hydrops. The theory is that reducing abnormal fluid pressure should decrease vertigo attacks and help protect hearing.
Betahistine is a histamine analog that acts primarily on H1 and H3 histamine receptors. These effects may influence both inner-ear circulation and vestibular processing in the brain.
| Effect | Proposed Benefit |
| Increases inner-ear blood flow | Improves endolymph regulation |
| Reduces hydrops | Reduces abnormal inner-ear fluid pressure |
| Improves inner-ear function | Fewer vertigo attacks and better hearing |
In simple terms, the traditional model is: better inner-ear circulation → less hydrops → fewer Meniere's attacks. This is the same fluid-pressure model underlying other traditional Meniere's treatments, including low salt diet for Meniere's and diuretics for Meniere's.
Betahistine May Not Work Because Hydrops Is Not The Cause
Betahistine may not reliably work for Meniere's disease because it was developed around the idea that endolymphatic hydrops causes the disease. Growing evidence instead suggests that hydrops may be an epiphenomenon, a downstream consequence of the disease rather than its underlying cause.
The evidence against hydrops as the primary cause is substantial:
- Hydrops can exist without Meniere's disease.
- Hydrops severity does not correlate with vertigo severity.
- Hydrops can remain stable during attacks.
- Treating hydrops does not stop Meniere's attacks.
- Hearing damage can occur before hydrops develops.
Taken together, these findings suggest that hydrops may be something Meniere's disease produces, rather than what produces Meniere's disease.
Meniere's Disease Is More Than an Inner-Ear Fluid Disorder
Betahistine is based on a relatively simple model: improve inner-ear circulation, reduce hydrops, and reduce attacks. But Meniere's disease increasingly appears to be a much more complex disorder.
We now believe Meniere's disease to be on a spectrum of atypical migraine disorders [13-17]. Migraine-related nerve and blood flow (vascular) mechanisms may help drive the attacks, while repeated episodes can produce lasting changes in the brain networks responsible for balance, sensory processing, autonomic regulation, and threat response.
This creates two distinct treatment targets:
- Control the disease: Reduce the migraine-related neural and vascular mechanisms that may drive attacks.
- Rehabilitate the brain: Restore the vestibular, sensory, autonomic, and neurocognitive networks affected by repeated attacks.
How Migraine is Involved in Meniere’s Disease
The evidence for an upstream migraine-related mechanism comes from several directions:
| Evidence | What It Shows |
| Epidemiologic overlap | About 50% of Meniere's patients have migraine [11] |
| Shared triggers | Stress, poor sleep, dehydration, weather, and certain foods can trigger both |
| Shared biological pathways | Trigeminal, vascular, and CGRP signaling can affect inner-ear function |
| Treatment response | 23 of 25 patients (92%) who failed conventional treatment improved with migraine-directed treatment |
| Longitudinal population data | Migraine increases the subsequent risk of Meniere's disease and its hallmark symptoms [12] |
Why Meniere's Disease Requires Multimodal Treatment
Stopping vertigo attacks is only part of the problem. Repeated vertigo can leave the brain's balance and sensory networks sensitized or poorly compensated, contributing to persistent dizziness, motion sensitivity, visual sensitivity, autonomic reactivity, and other symptoms between attacks.
This is why the alternative to betahistine is not simply another medication — even one directed towards migraine. Multimodal medical treatment for Meniere's must address both the mechanisms driving Meniere's disease and the neurological consequences it leaves behind.
| Treatment | Target |
| Migraine-directed treatment | Reduce the nerve, blood flow, and inflammatory biology driving attacks |
| Lifestyle medicine | Identify and reduce dietary, sleep, stress, and environmental triggers |
| Vestibular rehabilitation | Restore balance processing and reduce dizziness, motion, and visual sensitivity |
| Autonomic rehabilitation | Improve nervous-system regulation and reduce sympathetic overactivation |
| Neurocognitive rehabilitation | Normalize sensory processing, hypervigilance, and symptom reactivity |
| Tinnitus and sound therapy | Reduce tinnitus distress, sound sensitivity, and auditory reactivity |
What Doctors Miss About Betahistine for Meniere's Disease
The case against betahistine is broader than one negative clinical trial. Both the evidence for the drug and the disease model behind it have become increasingly difficult to support.
- Clinical evidence: The best controlled trial found no benefit over placebo, and systematic reviews remain inconclusive or very low certainty [1-3].
- Underlying theory: Betahistine targets inner-ear fluid and hydrops (extra fluid in the inner ear), but hydrops increasingly appears to be a downstream effect of the damage to the inner ear rather than the cause of Meniere's disease.
- Delayed treatment: Continued reliance on betahistine may delay treatment of the migraine-related neural and vascular mechanisms increasingly implicated in Meniere's disease.
- Unnecessary escalation: When symptoms persist, failure of conventional medical therapy may lead patients toward more invasive (surgery) or irreversible (gentamicin or labyrinthectomy) treatments before other noninvasive treatment approaches have been adequately explored.
Conclusion: Betahistine for Meniere's Doesn't Work
The best available evidence shows that betahistine does not work for Meniere's disease. The strongest placebo-controlled trial found no benefit, and systematic reviews continue to find insufficient or very low-certainty evidence supporting its use [1-4].
The larger problem may be the treatment target itself. Betahistine was developed around the hydrops model, while growing evidence suggests Meniere's disease involves upstream migraine-related biology and downstream changes in vestibular and sensory networks. If betahistine hasn't worked, the next step may not be another fluid-directed treatment, but a completely different treatment model.
Tried betahistine without lasting relief? Schedule a Program Consultation with us to learn about our multimodal treatment approach for Meniere's disease.
Betahistine for Meniere's Disease: FAQs
Does betahistine help Meniere's disease vertigo?
Betahistine has not been proven to reliably reduce vertigo attacks in Meniere's disease. Older and observational studies have suggested a possible benefit, but the BEMED trial, the strongest placebo-controlled Meniere's-specific trial, found no significant difference between placebo, low-dose betahistine, and high-dose betahistine over nine months [1,3-4]. The FDA has not found Betahistine to be effective and rejected their application in 1999.
Does betahistine prevent hearing loss in Meniere's disease?
There is no reliable evidence that betahistine prevents or slows hearing loss in Meniere's disease. In the BEMED trial, betahistine did not improve hearing outcomes, with results trending slightly worse compared with placebo.
Why isn't betahistine approved by the FDA?
Betahistine is not FDA-approved for Meniere's disease in the United States, and its effectiveness has not been established to the standard required for FDA approval. Its lack of approval should not be interpreted primarily as a safety concern; betahistine has been used extensively in other countries and has a long safety record [7], but the FDA has stated that there was not evidence that it was effective.
Is betahistine available in the United States?
Betahistine is not commercially available as an FDA-approved medication in the United States. When prescribed in the US, betahistine generally must be obtained through a compounding pharmacy or a Canadian pharmacy.
Is betahistine safe for Meniere's disease?
Betahistine generally has a favorable safety record despite uncertainty about its effectiveness for Meniere's disease. More than 130 million patients have reportedly been exposed worldwide, and its long history of international use has not identified major safety concerns that explain its lack of FDA approval.
How long does betahistine take to work for Meniere's disease?
There is no established timeframe in which betahistine has been proven to begin controlling Meniere's disease. Clinical studies have evaluated treatment over periods of months to years, including nine months in the BEMED trial, but that trial did not find better vertigo control with betahistine than with placebo [3].
Are there new forms of betahistine being studied?
Yes. Researchers are investigating new ways to increase betahistine delivery and bioavailability. Recent studies have evaluated intranasal betahistine, betahistine combined with selegiline to increase absorption, and intratympanic (injection behind the ear drum) delivery in animals [8-10]. None has yet demonstrated improved outcomes specifically for Meniere's disease.
What happens if betahistine doesn't work for Meniere's disease?
If betahistine doesn't work, it does not mean that conservative treatment for Meniere's disease has been exhausted. Treatment can shift away from another fluid-directed therapy toward a multimodal approach addressing migraine-related mechanisms, vestibular (balance organ) dysfunction, autonomic (nerve related) regulation, sleep, nutrition, and other factors contributing to attacks and persistent symptoms.
What are alternatives to betahistine for Meniere's disease?
Alternatives to betahistine include conventional Meniere's treatments and migraine-informed multimodal medical rehabilitation. Depending on the patient, treatment may include migraine-directed medical therapy, nutritional and hydration management, vestibular rehabilitation, autonomic rehabilitation, neurocognitive treatment, sleep optimization, and management of tinnitus or sound sensitivity.
What's the difference between betahistine and diuretics for Meniere's disease?
Betahistine and diuretics work differently, but both have traditionally been used within the fluid-regulation model of Meniere's disease. Betahistine is proposed to improve inner-ear circulation and endolymph regulation, while diuretics alter systemic salt and fluid balance. Neither has strong evidence demonstrating reliable prevention of Meniere's attacks [1].
Betahistine for Meniere's Disease: References
- Webster KE, Galbraith K, Harrington-Benton NA, et al. Systemic Pharmacological Interventions for Meniere's Disease. Cochrane Database of Systematic Reviews. 2023.
- Van Esch B, van der Zaag-Loonen H, Bruintjes T, van Benthem PP. Betahistine in Meniere's Disease or Syndrome: A Systematic Review. Audiology and Neurotology. 2021.
- Adrion C, Fischer CS, Wagner J, Gurkov R, Mansmann U, Strupp M; BEMED Study Group. Efficacy and Safety of Betahistine Treatment in Patients With Meniere's Disease (BEMED Trial). BMJ. 2016;352:h6816.
- Murdin L, Hussain K, Schilder AG. Betahistine for Symptoms of Vertigo. Cochrane Database of Systematic Reviews. 2016.
- Molnar A, Maihoub S, Tamas L, Szirmai A. Conservative Treatment Possibilities of Meniere Disease, Involving Vertigo Diaries. Ear Nose Throat J. 2021;100:536-542. PMID: 31617407.
- Basura GJ, Adams ME, Monfared A, et al. Clinical Practice Guideline: Meniere's Disease. Otolaryngology-Head and Neck Surgery. 2020;162(2_suppl):S1-S55.
- Jeck-Thole S, Wagner W. Betahistine: A Retrospective Synopsis of Safety Data. Drug Safety. 2006.
- Van de Heyning P, Betka J, Chovanec M, et al. Efficacy and Safety of Intranasal Betahistine in the Treatment of Surgery-Induced Acute Vestibular Syndrome: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Study. Otology & Neurotology. 2023;44:493-501. PMID: 37026797.
- Strupp M, Churchill GC, Naumann I, et al. Examination of Betahistine Bioavailability in Combination With the Monoamine Oxidase B Inhibitor, Selegiline, in Humans (PK-BeST). Frontiers in Neurology. 2023;14:1271640. PMID: 37920833.
- Spiegel JL, Situ Y, Ungar OJ, et al. Intratympanic Application of Betahistine for Meniere Disease: An Animal Study on Safety and Diffusion to the Inner Ear. Otology & Neurotology. 2026 Jul 10. PMID: 42430787.
- Kim SY, Lee CH, Yoo DM, et al. Association Between Meniere Disease and Migraine. JAMA Otolaryngology-Head & Neck Surgery. 2022.
- Bhatt K, Ren Y, Chan C, Rara M, Djalilian HR, Abouzari M. Meniere's Disease and Migraine: Effect of Migraine Medications on Symptoms of Meniere's Disease. Laryngoscope. 2026 Apr 21. doi:10.1002/lary.70578. PMID: 42018740; PMCID: PMC13170467.
- Tawk K, Kim JK, Frank M, Goshtasbi K, Abouzari M, Djalilian HR. Correlation Between Laterality of Hearing Loss and Migraine Features in Menière's Disease. Otol Neurotol. 2023 Aug 1;44(7):651-655.
- Frank M, Abouzari M, Djalilian HR. Meniere's disease is a manifestation of migraine. Curr Opin Otolaryngol Head Neck Surg. 2023 Oct 1;31(5):313-319.
- Tawk K, Kim JK, Frank M, Goshtasbi K, Abouzari M, Djalilian HR. Correlation Between Laterality of Hearing Loss and Migraine Features in Menière's Disease. Otol Neurotol. 2023 Aug 1;44(7):651-655.
- Abouzari M, Aryan N, Djalilian HR. The Bidirectional Relationship Between Migraine and Meniere Disease. JAMA Otolaryngol Head Neck Surg. 2022 Sep 1;148(9):894.
- Ghavami Y, Haidar YM, Moshtaghi O, Lin HW, Djalilian HR. Evaluating Quality of Life in Patients With Meniere's Disease Treated as Migraine. Ann Otol Rhinol Laryngol. 2018 Dec;127(12):877-887.
